Immunologic clustering of donor-specific antibodies and clinical outcomes in kidney transplant recipients

Table 1 Patient demographics and baseline characteristics

Variable	Category	n (%)
Recipient gender	Female	54 (48.2)
	Male	58 (51.8)
Donor gender	Female	35 (31.2)
	Male	77 (68.8)
Donor type	Deceased	8 (7.1)
	Living	104 (92.9)
DSA presence	Present	112 (100.0)
Induction therapy	ATG only	108 (96.4)
	Basiliximab only	4 (3.6)
Sensitizing events	None	103 (92.0)
	Pregnancy	5 (4.5)
	Blood Transfusion	4 (3.5)
Maintenance therapy	CSA + MMF + PRED	1 (0.9)
	FK + MMF + PRED	111 (99.1)
Pre-transplant desensitization	No	60 (53.6)
	Yes	52 (46.4)
Previous transplant	No	109 (97.3)
	Yes	3 (2.7)
IVIG use	No	45 (40.2)
	Yes	67 (59.8)
Variable	Median	IQR/unit
Recipient age (years)	46.0	35.0-60.0
Donor age (years)	35.0	29.0-43.2
ATG dose (mg/kg)	5.0	4.0-5.0
Length of stay (days)	9.0	8.0-12.0
Creatinine-4 months (μmol/L)	90.0	72.0-112.0
Creatinine-1 year (μmol/L)	83.0	72.5-107.0
Creatinine-2 years (μmol/L)	82.0	69.2-104.5
eGFR-4 months (mL/minute)	78.0	62.5-96.2
eGFR-1 year (mL/minute)	86.0	67.0-99.5
eGFR-2 years (mL/minute)	86.5	72.5-102.0

DSA: Donor-specific antibody; ATG: Anti-thymocyte globulin; CSA: Cyclosporine A; FK: Tacrolimus; MMF: Mycophenolate mofetil; PRED: Prednisolone; IVIG: Intravenous immunoglobulin; eGFR: Estimated glomerular filtration rate; IQR: Interquartile range.